Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Yeditepe Universitesi has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination paths for each listed action.
PALLAY, MICHAEL B is the busiest examiner, with 1 pending matter. Counsel should use matter-specific responses and avoid relying on a common examiner strategy, while maintaining consistent objectives across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.8% | +33.8% |
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18872899 | ANTI-CANCER FORMULATION COMPRISING SODIUM PENTABORATE, CURCUMIN AND PIPERINE FOR USE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA | PALLAY, MICHAEL B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18872899 | ANTI-CANCER FORMULATION COMPRISING SODIUM PENTABORATE, CURCUMIN AND PIPERINE FOR USE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA | PALLAY, MICHAEL B | — |
| 18864037 | USE OF SODIUM PENTABORATE PENTAHYDRATE AS A CHEMOTHERAPEUTIC AGENT | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1615 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18872899 | ANTI-CANCER FORMULATION COMPRISING SODIUM PENTABORATE, CURCUMIN AND PIPERINE FOR USE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA | PALLAY, MICHAEL B | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18864037 | USE OF SODIUM PENTABORATE PENTAHYDRATE AS A CHEMOTHERAPEUTIC AGENT | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 17924699 | METHOD OF PRODUCING PLANT-DERIVED EXOSOMES | DELEO, VICTORIA LYNN | 1662 | §103 | Final Rejection | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYeditepe Universitesi has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Michael B Pallay has the most, with 1 of Yeditepe Universitesi's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
